Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.
Epistemonikos ID: 1dee4dd3eb4a84e374ef5167be6631ca382790c7
First added on: May 12, 2024